This award recognizes the quality and performance of the ERBC Group's CSR approach, which is reflected not only in the concrete actions of its employees, but also in the company's initiatives with its stakeholders, including its partners and customers.

This award recognizes the quality and performance of the ERBC Group's CSR approach, which is reflected not only in the concrete actions of its employees, but also in the company's initiatives with its stakeholders, including its partners and customers.

- This strategic addition expands ERBC Group's non-clinical derisking capabilities to include efficacy, biodistribution, mechanistic and proof of concept studies based on in vitro and in vivo models combined with high-resolution imaging in a wide range of small animal species.

- Voxcan’s core businesses have been in oncology, viral and bacterial infectious diseases, osteo-articular inflammatory diseases and medical devices for 16 years.

- This acquisition is in line with ERBC's 3R policy and commitment to reduce the number of animals (up to 80%) used i

ETISENSE (Lyon) and the EUROPEAN RESEARCH BIOLOGY CENTER (ERBC Group) announce a collaboration to develop and validate the DECRO telemetry solution for marmosets, a new world primate with several advantages in non-clinical studies.

The collaboration between ETISENSE and ERBC Group aims to develop and validate the DECRO telemetry solution on a new species: the marmosets, which are considered today as an easy to handle and economically attrac

This strategic acquisition expands ERBC Group’s non-clinical research and development testing portfolio, adding in ovo models for anticancer drug development.

UI Investissement, alongside MACSF, is supporting the development of ERBC Group, specialized in non-clinical research performing the evaluation of drug candidates for pharmaceutical and biotechnology companies.
ERBC's ambition, through both organic and external growth, is to become the leading independent European non-clinical CRO.

ERBC, Oncodesign, Cynbiose, Aepodia and PharmaLex a.r.c.

ERBC: the leading independent European Contract Research Organization (CRO), expert in Pharmacology and Toxicology

• The European Research Biology Center (ERBC) offers a new non-clinical full-service and an expected alternative in the more and more concentrated world of "CRO’s"
• An exhaustive panel of preclinical models and of toxicology/pre-IND regulatory packages, from study design to reports, merging more than 80 years of cumulated experience between CERB, France and RTC, Italy